Pliant Therapeutics presents data from its Bexotegrast program
PremiumThe FlyPliant Therapeutics presents data from its Bexotegrast program
2M ago
Pliant Therapeutics assumed with an Outperform at Leerink
Premium
The Fly
Pliant Therapeutics assumed with an Outperform at Leerink
2M ago
Pliant Therapeutics price target raised to $38 from $36 at H.C. Wainwright
Premium
The Fly
Pliant Therapeutics price target raised to $38 from $36 at H.C. Wainwright
3M ago
Truist biotech analyst holds an analyst/industry conference call
PremiumThe FlyTruist biotech analyst holds an analyst/industry conference call
4M ago
Pliant Therapeutics management to meet with Piper Sandler
Premium
The Fly
Pliant Therapeutics management to meet with Piper Sandler
4M ago
Pliant Therapeutics presents data from Bexotegrast program at EASL Congress
Premium
The Fly
Pliant Therapeutics presents data from Bexotegrast program at EASL Congress
5M ago
Pliant Therapeutics price target lowered to $36 from $48 at H.C. Wainwright
PremiumThe FlyPliant Therapeutics price target lowered to $36 from $48 at H.C. Wainwright
6M ago
Pliant Therapeutics price target lowered to $44 from $45 at Citi
Premium
The Fly
Pliant Therapeutics price target lowered to $44 from $45 at Citi
6M ago
Pliant Therapeutics reports Q1 EPS (78c), consensus (77c)
Premium
The Fly
Pliant Therapeutics reports Q1 EPS (78c), consensus (77c)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100